Clinical trials: Idiopathic Lung Fibrosis
Idiopathic Pulmonary Fibrosis
Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.
- Trial name
- NCT01214187
- Testing
- inhaled carbon monoxide, Oxygen
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Brigham and Women's Hospital
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA1 (NCT03711162)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Australia and 13 more
- Volunteers
- 525 people
- Sponsor
- Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA2 (NCT03733444)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Argentina and 13 more
- Volunteers
- 781 people
- Sponsor
- Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
- Trial name
- IPF-201 (NCT04072315)
- Testing
- PLN-74809, Knottin tracer
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pliant Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis, Cough
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough.
- Trial name
- NCT00600028
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Idiopathic Pulmonary Fibrosis
Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)
Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases.
- Trial name
- NCT03562247
- Testing
- Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, double-blind, placebo-controlled safety and tolerability study of N-acetylcysteine or placebo in participants with mild to moderate idiopathic pulmonary fibrosis (IPF) receiving background…
- Trial name
- NCT02707640
- Testing
- N-acetylcysteine, Pirfenidone
- Where
- 69 sites in Austria, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
- Trial name
- QUALIFY IPF (NCT03710824)
- Testing
- Nintedanib
- Where
- 10 sites in Greece
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and…
- Trial name
- NCT00287716
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 435 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older.
- Trial name
- NCT05321069
- Testing
- BI 1015550
- Where
- 334 sites in United States, Argentina and 35 more
- Volunteers
- 1,177 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise…
- Trial name
- NCT02803580
- Where
- 18 sites in Italy
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared…
- Trial name
- CANAL (NCT04030026)
- Testing
- NAL ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF.
- Trial name
- NCT02598193
- Testing
- Nintedanib, Pirfenidone
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic…
- Trial name
- MSC in IPF (NCT01385644)
- Testing
- Placental MSC
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- The Prince Charles Hospital
Idiopathic Pulmonary Fibrosis
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic…
- Trial name
- BUILD OL (NCT00631475)
- Testing
- Bosentan
- Volunteers
- 128 people
- Sponsor
- Actelion
Pulmonary Fibrosis
Supplemental Oxygen in Pulmonary Fibrosis
To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change…
- Trial name
- NCT01961362
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences